Current advances on multi-specific immune cell engagers for brain tumor treatment are reviewed and novel insights into overcoming existing challenges are provided.
Abstract
Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumors advance and metastasize, prompting the need for new treatment modalities. Recent innovations in antibody-based immunotherapies may complement brain cancer treatment. Biotechnical engineering platforms yield new antibody-inspired biomolecules for optimal engagement of specific and tumor-associated antigens, which also recruit and elicit immune effector cell functions. Here, we review current advances on multi-specific immune cell engagers for brain tumor treatment and provide novel insights into overcoming existing challenges.
It is highlighted that while cancer vaccines consistently induce robust systemic immune responses, their clinical efficacy is limited by profound tumor heterogeneity and a highly immunosuppressive tumor microenvironment.
Andres Santos, E. Chiocca· Hematology/Oncology Clinics...· 0 citations
This review summarizes the main immunotherapeutic approaches currently investigated, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and oncolytic viruses, and examines the key biological factors responsible for treatment resistance.
D. Slavkov, S. Troyanova-Slavkova· Cancer Immunology Connect· 0 citations
Simple Summary Brain tumors are the most common solid cancer in children and the leading cause of childhood cancer deaths. While these tumors are difficult to treat, immunotherapy—a treatment that helps the body’s own immune system fight cancer—is showing great promise for young patients. The three main modalities of i...
Irem Yenidogan, Nirav Thacker, Anirban Das et al.· Current Oncology· 1 citation
Glioblastoma accounts for 14.5% of all central nervous system (CNS) tumours. Current immunotherapeutic strategies include surgery, radiotherapy, and chemotherapy, with an increased focus on checkpoint inhibitors and CAR-T cell therapy. However, these have demonstrated limited clinical effectiveness due to the tumour’s...
Eisha Abid Ali, K. Bano, Hajira Ali et al.· JOURNAL OF PAKISTAN MEDICAL...· 0 citations
This comprehensive review delves into recent advances in modern therapeutic approaches that aim to enhance the efficacy of conventional treatments for rare brain metastases from breast cancer and systematically evaluates emerging strategies such as advanced drug delivery technologies, including nanoparticles (NPs), pol...
Ghazala Muteeb, Aya Y El-Sayed, Mohamed S. AboHoussien et al.· SLAS discovery : advancing l...· 0 citations
